Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:30 | Fractyl Health prices $60 million common stock offering at $1 per share | 2 | Investing.com | ||
13:30 | Fractyl Health stock gains after pricing of $60M underwritten offering | 2 | Seeking Alpha | ||
FRACTYL HEALTH Aktie jetzt für 0€ handeln | |||||
13:22 | Fractyl Health platziert Aktien im Wert von 60 Millionen US-Dollar zu 1 US-Dollar pro Stück | 5 | Investing.com Deutsch | ||
13:18 | Fractyl's Revita shows promise in preventing weight regain after GLP-1 use | 3 | Investing.com | ||
13:12 | Fractyl Health, Inc.: Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
13:06 | Fractyl Health, Inc.: Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation | 117 | GlobeNewswire (Europe) | Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain... ► Artikel lesen | |
13:05 | FRACTYL HEALTH, INC. - 8-K, Current Report | 2 | SEC Filings | ||
15.09. | Fractyl Health: H.C. Wainwright startet Coverage mit "Buy"-Einstufung | 3 | Investing.com Deutsch | ||
15.09. | Fractyl Health stock initiated with Buy rating at H.C. Wainwright | 1 | Investing.com | ||
03.09. | Fractyl Health, Inc.: Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth | 1 | GlobeNewswire (USA) | ||
03.09. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
14.08. | Canaccord Genuity lowers Fractyl Health stock price target to $6 from $12 | 2 | Investing.com | ||
13.08. | Fractyl Health outlines upcoming REMAIN-1 and Rejuva milestones while strengthening cash position | 1 | Seeking Alpha | ||
12.08. | Fractyl Health: Höhere F&E-Ausgaben führen zu größerem Verlust, Liquidität jedoch bis 2026 gesichert | 1 | Investing.com Deutsch | ||
12.08. | Fractyl Health reports Q2 results | 1 | Seeking Alpha | ||
12.08. | FRACTYL HEALTH, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
11.08. | An Overview of Fractyl Health's Earnings | 1 | Benzinga.com | ||
07.08. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
07.08. | Fractyl Health raises $23 million in public offering with warrants | 3 | Investing.com | ||
06.08. | Fractyl Health stock plunges after $20 million public offering | 2 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 83,25 | -1,07 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., Tübingen | Datum der Anmeldung:18.09.2025Aktenzeichen:B3-86/25Unternehmen:BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., TübingenProduktmärkte:biotechnologische... ► Artikel lesen | |
CUREVAC | 4,556 | -0,61 % | CureVac-Aktie vor FINANZ-DRAMA: Droht ein neuer Crash?!! | ||
AMGEN | 230,75 | -0,82 % | Amgen Expands $650 Mln U.S. Manufacturing Network; Creates Around 750 Jobs | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), a biotechnology company, on Friday announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.The company... ► Artikel lesen | |
NOVAVAX | 7,040 | -1,63 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BIOGEN | 117,55 | +0,99 % | Biogen Inc.: LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia | TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
MAINZ BIOMED | 1,550 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt den Beginn der Vermarktung von ColoAlert® in der Schweiz bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Markteinführung
Mainz Biomed gibt den Beginn der Vermarktung von ColoAlert® in der Schweiz bekannt
23.09.2025... ► Artikel lesen | |
VIKING THERAPEUTICS | 21,465 | -0,28 % | Viking Therapeutics: Wo bleibt der nächste Katalysator? | Der Wettbewerb im Markt für Adipositas- und Diabetesmedikamente nimmt weiter Fahrt auf. Während Konkurrenten durch milliardenschwere Übernahmen Schlagzeilen machen, kämpft Viking Therapeutics mit gemischten... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 13,270 | -6,88 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy | One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical... ► Artikel lesen | |
TEMPUS AI | 67,00 | +0,75 % | AKTIONÄR-Tipp Tempus AI: Zulassung sorgt für Allzeithoch | Starke Performance der Aktie von Tempus AI. Das Papier des amerikanischen KI-Spezialisten ist in der laufenden Handelswoche auf ein neues Rekordhoch bei 97,79 Dollar gesprintet. Für positive Impulse... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,476 | -1,37 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,180 | -0,10 % | BMO upgrades Sarepta on Elevidys uptake, pipeline prospects | ||
BIOMARIN PHARMACEUTICAL | 44,860 | -0,60 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
EXELIXIS | 33,210 | +0,09 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,911 | -2,15 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,056 | +1,38 % | PacBio enters high-throughput carrier screening market with expanded test suite |